Ibrexafungerp, sold under the brand name Brexafemme, is an antifungal medication used to treat vulvovaginal candidiasis (VVC) (vaginal yeast infection). It is taken orally (by mouth). It is also currently undergoing clinical trials for other indications via an intravenous (IV) formulation. An estimated 75% of women will have at least one episode of VVC and 40 to 45% will have two or more episodes in their lifetime. Ibrexafungerp is the first triterpenoid antifungal to be FDA approved. It acts via inhibition of glucan synthase, which prevents formation of the fungal cell wall.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage |
|
Link from a Wikipage to an external page | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC prefix |
|
c |
|
CAS number |
|
ChEMBL |
|
class | |
DrugBank |
|
elimination half-life |
|
H |
|
index2 label |
|
IUPAC name |
|
KEGG |
|
legal US |
|
metabolism |
|
n |
|
O |
|
pregnancy category |
|
PubChem |
|
routes of administration | |
SMILES |
|
StdInChI |
|
StdInChIKey |
|
synonyms |
|
tradename |
|
UNII |
|